The BTI research group is committed to dermatology and is making an extensive clinical effort to develop new Endoret indications and application protocols, thus improving the quality of treatment in a wide range of clinical situations.
Due to its ability to stimulate tissues, its anti-inflammatory potential and its bacteriostatic effect, Endoret® (PRGF®) has great potential as a treatment for capillary and dermatological conditions.
Three formulations in one single product
The fact that it's in liquid form facilitates skin infiltration.
It is an activated liquid form that, following tissue infiltration, polymerises in a Fibrin Matrix allowing the balanced and gradual release of a large number of molecules, including growth factors and other proteins.
This formulation is used in minimally invasive treatments such as:
Arterial and venous ulcers
The plasma rich in growth factors clot is a Fibrin Matrix that polymerises after controlled activation with calcium.
In combination with the other formulations in surgical treatments, it favours tissue regeneration and acts as an excellent system for the balanced and gradual release of a high number of molecules, including growth factors and other proteins.
The plasma rich in growth factors PRGF serum is a formula made up of inert plasma proteins, growth factors and other bioactive molecules for topical use with the consistency of a cream/serum.
It is used to treat ulcers, wounds and to improve the quality and health of the skin.
It can be stored at 4ºC or in the fridge for 6 months.
Want to know more about Endoret® (PRGF®) in Dermatology?